Page 1

Manavex LIFE SCIENCES Corp. Source : Anavex Life Sciences Corp. July 30 , 2026 08:00 ET Anavex Life Sciences Reports Preliminary Second Quarter 2026 Financial Results and Provides Business Update Establishing Disciplined , Data - Driven Strategy with Focus on FDA Engagement for Alzheimer's Disease NEW YORK , July 30 , 2026 ( GLOBE NEWSWIRE ) -- Anavex Life Sciences Corp. ( Anavex or the Company ) ( Nasdaq : AVXL ) , a clinical - stage biopharmaceutical company focused on developing innovative treatments for central nervous system ( CNS ) diseases with high unmet medical needs , today reported preliminary financial results for its fiscal second quarter ended March 31 , 2026. The Company's primary focus is on advancing its lead compound ANAVEX® 2-73 ( blarcamesine ) in the Company's clinical program for the treatment of mild cognitive impairment ( " MCI " ) due to Alzheimer's disease ( " AD " ) and mild AD ( collectively known as “ early AD " ) , and for Rett syndrome and Fragile X syndrome , both of which are neurodevelopmental rare diseases . " Anavex remains firmly committed to our lead candidate oral blarcamesine ( ANAVEXⓇ2-73 ) for patients with Alzheimer's disease , and we are prioritizing engagement with the U.S. FDA to align on a clear , data - driven regulatory and clinical development strategy , " stated Terrie Kellmeyer , PhD , Interim Chief Executive Officer . " A qualified data - driven approach will guide every decision we make . I have spent nearly three decades building and leading clinical and regulatory functions in drug development , and I'm bringing that experience to bear every day as we implement a disciplined regulatory strategy and build the right foundation for our programs . We are committed to advancing blarcamesine towards a clear regulatory path . I also want to recognize our employees , who have continued to show up for the patients who are counting on us , and the patients and families living with Alzheimer's disease , Rett syndrome and Fragile X , who are depending on us to continue this important work on these urgent unmet medical needs . We are continuing to execute on the mission of developing targeted , orally delivered therapies for a specific range of CNS related diseases . " Business Update & Anticipated Upcoming Milestones • Anavex is prioritizing programs that the Company believes have the greatest potential for success . The strategy concentrates resources on blarcamesine across three CNS indications : early Alzheimer's disease and Rett syndrome , where the Company's clinical and regulatory foundation is most advanced , and Fragile X , where FDA Orphan Drug Designation , supportive